Halozyme Therapeutics (HTI) Adopts SEC Rule 10b5-1 Policy
More News related to HTI
- Halozyme Therapeutics (HTI) Adopts SEC Rule 10b5-1 Policy
- Halozyme Therapeutics (HTI) Misses Q4 EPS by 1c
- StreetInsider.com Pre-Open Movers 12/06
- Halozyme Therapeutics (HTI) Soars on Deal with Roche
- Halozyme Therapeutics (HTI) Announces Agreement with Roche for the Application of Enhanze
More News related to Insider Trades
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
Halozyme Therapeutics, Inc. (Amex: HTI) has adopted a policy that provides for the use of pre-arranged trading plans by persons subject to the company's insider trading policy. All such pre-arranged trading plans must (i) comply with certain guidelines established by Halozyme, including volume limitations, (ii) be approved by a committee consisting of independent directors and the company's Chief Financial Officer and (iii) comply with Rule 10b5-1 established by the Securities and Exchange Commission.
Related Categories
Insider TradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
